Phase 3 Readout~month

Phase 3 Topline: EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Eva

Name: Phase 3 Topline: EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Eva
Start: 2028-10-01

October 1, 2028

Company: Stoke Therapeutics, Inc. (STOK)
Indication: Dravet Syndrome

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Eva — STOK Phase 3 Readout | BioSniper